Join the quest to save rock, as Activision Publishing, Inc.’s (Nasdaq: ATVI) highly-anticipated Guitar Hero®: Warriors of Rock hits store shelves nationwide today. Featuring the largest on-disc set-list ever in a Guitar Hero® game, Guitar Hero: Warriors of Rock’s furious finger-fretting rock music collection is headlined by some of the largest bands in rock and includes original tracks, re-records and bands making their Guitar Hero debut. With the all-new, rock inspired guitar controller, gamers will embark on an epic journey from the halls of punk music to the lava fields of rock treachery in the first ever Guitar Hero story-driven Quest Mode narrated by KISS front man Gene Simmons. Additionally, challenge hungry achievement junkies will find the game’s all-new Quickplay+ up to par as they strive to master the 13 star challenges packed into every one of the 90+ on-disc songs as well as every song in their Guitar Hero music library. Heightening the rock experience, the first album from Soundgarden in over 10 years, Telephantasm, will be bundled with one million Guitar Hero: Warriors of Rock launch units.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/guitarhero/46201/
Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
Johnson & Johnson today honors the winners of the 2012 Dr. Paul Janssen Award for Biomedical Research in a ceremony and scientific symposium at the New York Academy of Sciences in New York, NY. Victor Ambros, Ph.D., of the University of Massachusetts Medical School, and Gary Ruvkun, Ph.D., of Massachusetts General Hospital and Harvard Medical School, received the award for their collaborative discovery of microRNAs (miRNAs) as central regulators of gene expression and development, and will share a $100,000 prize.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58019-johnson-and-johnson-jnj-2012-dr-paul-janssen-award-for-biomedical-research
Beim großen Golf GTI-Treffen am Wörthersee enthüllte Audi seinen TT ultra quattro concept - eine Technikstudie, die minimales Gewicht und maximale Sportlichkeit vereint. Diese Sportlichkeit bekamen die Fans auch von der breiten Palette der High-Performance-Cars geboten. Neben dem legendären Sport quattro S1 standen aktuelle RS-Modelle und reinrassige Rennboliden zur Schau. Und auch der Audi R18 e-tron quattro war am See dabei. Im Mittelpunkt des Audi-Auftritts stand aber das TT ultra quattro concept. Das Showcar vereint schlanke 1.111 Kilogramm Gesamtgewicht mit einem 2.0 TFSI-Motor, dessen 228 kW/310 PS und 400 Nm leichtes Spiel mit dem Coupé haben. Aus dem Stand katapultiert sich der TT ultra quattro concept in 4,2 Sekunden auf 100 km/h. Sein Leistungsgewicht von 3,6 kg/PS liegt auf dem Niveau reinrassiger Supersportwagen. Und es lohnt sich auch der Blick ins Detail, schließlich macht das Konzeptauto den automobilen Leichtbau sichtbar. Schon das aktuelle Serienauto mit einem Karosserie-Gewicht von nur 206 Kilogramm plus 98 Kilogramm für die Anbauteile ist ein Beleg für die hohe Leichtbau-Kompetenz von Audi. Für die Karosserie des Wörthersee-Showcars haben die Ingenieure aus Ingolstadt und Neckarsulm den Audi Space Frame (ASF) der aktuellen TT-Generation konsequent weiterentwickelt und die Karosseriestruktur noch einmal um 43 Kilogramm abgespeckt. Zusammen mit den optimierten Anbauteilen ergeben sich 100 Kilogramm Gewichtseinsparung. Die Kombination aus Leichtigkeit und Sportlichkeit spiegelt sich auch in der Optik wieder. Im Vergleich zum Serienmodell haben die Audi Designer die Konturen des Showcars noch einmal deutlich gestrafft. Mit seinen großen Spoilern stellt der TT ultra quattro concept seine Motorsport-Gene zur Schau. So ist der Fuß des Heckflügels als tragendes Bauteil aus gefrästem Aluminium gefertigt, der Flügel als funktionales Element hingegen aus sichtbarem Carbon. Zu den weiteren Highlights am Wörthersee zählte der neue Audi RS 6 Avant. Das Hochleistungsmodell der quattro GmbH bietet mehr Effizienz und stärkere Fahrleistungen bei verringertem Gewicht. Und natürlich durfte auch der neue RS 7 Sportback fehlen. Sein starkes Herz ist ebenfalls der 4.0 TFSI V8 Biturbo. Die Leistung von 412 kW / 560 PS liegt im Bereich von 5.700 bis 6.600 Umdrehungen an. Zwischen 1.750 und 5.500 1/min sind konstant 700 Nm Drehmoment verfügbar. Neben dem raketenartigen Schub ist der Sound ein wichtiger Bestandteil des Fahrerlebnisses: Auf Tastendruck und beim kräftigen Gas geben sorgen schaltbare Klappen in der Abgasanlage für einen noch volleren Klang, optional montiert Audi eine Sport-Abgasanlage. Ebenso auf dem Audi Stand präsentierte sich der neue Audi RS Q3 als erstes RS-Modell in der erfolgreichen Q Familie. Es ist das vierte Modell, das die quattro GmbH in diesem Jahr auf den Markt bringen wird. Mit dem 2.5 TFSI-Motor, der mit einer Spitzenleistung von 228 kW /310 PS aufwartet, steckt ein preisgekrönter Hochleistungsmotor unter der Haube des RS Q3.
Weight loss is perhaps the most common New Year’s resolution made and likely the most difficult to keep. Amway North America offers the NUTRILITE® Weight Management Program, which includes a genetic test that helps individuals find their genotype-matched diet, and offers weight management plans matched to that gene test’s results.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53285-amway-nutrilite-weight-management-program-new-year-resolutions-julie-upton
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
A Princess of Roumania fantasy, with an extraordinary, intense, compressed SF novel in three parts, each set in its own alternate-history universe. The sections are all rooted in Virginia and the Battle of the Crater, and are also grounded in the real history of the Park family, from differing points of view.
The first section is set in the aftermath of the Civil War, in a world in which the Queen of the North has negotiated a two-nation settlement. The second, taking place in northwestern Massachusetts, investigates a secret project during World War II, in a time somewhat like the present. The third is set in the near-future United States, with aliens from history.
The cumulative effect is awesome. There hasn’t been a three part novel this ambitious in science fiction since Gene Wolfe’s classic The Fifth Head of Cerberus. Find out more at http://us.macmillan.com/allthosevanishedengines/PaulPark Fantasy/Scifi
